Palvella Therapeutics (PVLA) Non-Current Deffered Revenue (2016 - 2023)
Historic Non-Current Deffered Revenue for Palvella Therapeutics (PVLA) over the last 8 years, with Q2 2023 value amounting to $759000.0.
- Palvella Therapeutics' Non-Current Deffered Revenue fell 9655.99% to $759000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $759000.0, marking a year-over-year decrease of 9655.99%. This contributed to the annual value of $18.7 million for FY2022, which is 5121.74% down from last year.
- Latest data reveals that Palvella Therapeutics reported Non-Current Deffered Revenue of $759000.0 as of Q2 2023, which was down 9655.99% from $11.7 million recorded in Q1 2023.
- In the past 5 years, Palvella Therapeutics' Non-Current Deffered Revenue ranged from a high of $59.7 million in Q1 2019 and a low of $759000.0 during Q2 2023
- Moreover, its 5-year median value for Non-Current Deffered Revenue was $37.4 million (2020), whereas its average is $34.9 million.
- As far as peak fluctuations go, Palvella Therapeutics' Non-Current Deffered Revenue skyrocketed by 3058.79% in 2021, and later tumbled by 9655.99% in 2023.
- Over the past 5 years, Palvella Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $47.3 million in 2019, then dropped by 24.03% to $35.9 million in 2020, then grew by 6.97% to $38.4 million in 2021, then plummeted by 51.22% to $18.7 million in 2022, then plummeted by 95.95% to $759000.0 in 2023.
- Its last three reported values are $759000.0 in Q2 2023, $11.7 million for Q1 2023, and $18.7 million during Q4 2022.